Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Steroid Dependent/Refractory cGVHD
NCT04232397Phase 2Terminated
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in chronic graft-versus-host disease (cGVHD), sponsored by Shanghai General Hospital. Started Apr 2020; status: terminated.
02
Drugs
anlotinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04232397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232397.